These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34723856)

  • 1. First pharmacokinetic data of bictegravir in pregnant women living with HIV.
    Bukkems VE; Hidalgo-Tenorio C; Garcia C; van Hulzen AGW; Richel O; Burger DM; Colbers AP;
    AIDS; 2021 Nov; 35(14):2405-2406. PubMed ID: 34723856
    [No Abstract]   [Full Text] [Related]  

  • 2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bictegravir: First Global Approval.
    Markham A
    Drugs; 2018 Apr; 78(5):601-606. PubMed ID: 29564777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
    Lagoutte-Renosi J; Flammang M; Ducloux D; Bamoulid J; Royer PY; Lepiller Q; Clairet AL; Davani S; Muret P
    J Chemother; 2022 May; 34(3):199-202. PubMed ID: 34180378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches.
    Martin C; Unal G; Plantier JC; Alessandri-Gradt E
    J Antimicrob Chemother; 2022 Jul; 77(8):2305-2307. PubMed ID: 35488848
    [No Abstract]   [Full Text] [Related]  

  • 12. Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir.
    Soudeyns H; Dumond J
    AIDS; 2020 Nov; 34(14):2137-2139. PubMed ID: 33105171
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
    Gelé T; Chéret A; Castro Gordon A; Nkam L; Furlan V; Pallier C; Becker PH; Catalan P; Goujard C; Taburet AM; Gasnault J; Gouget H; Barrail-Tran A
    J Antimicrob Chemother; 2021 Nov; 76(12):3280-3285. PubMed ID: 34508640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
    Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
    Tempestilli M; D'Avolio A; De Nicolò A; Agrati C; Antinori A; Cicalini S
    J Antimicrob Chemother; 2021 Nov; 76(12):3320-3322. PubMed ID: 34450632
    [No Abstract]   [Full Text] [Related]  

  • 16. Bictegravir and dolutegravir: head to head at 96 weeks.
    Barber TJ
    Lancet HIV; 2019 Jun; 6(6):e342-e343. PubMed ID: 31068271
    [No Abstract]   [Full Text] [Related]  

  • 17. Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report.
    Lê MP; Ferré VM; Mazy F; Bourgeois-Moine A; Damond F; Matheron S; Descamps D; Ghosn J; Peytavin G
    J Antimicrob Chemother; 2022 Feb; 77(3):851-853. PubMed ID: 34792155
    [No Abstract]   [Full Text] [Related]  

  • 18. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
    Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
    Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
    Bachelard A; Isernia V; Vallois D; Le Gac S; Chalal L; Landman R; Damond F; Descamps D; Yazdanpanah Y; Peytavin G; Ghosn J
    J Antimicrob Chemother; 2021 Aug; 76(9):2484-2485. PubMed ID: 34109414
    [No Abstract]   [Full Text] [Related]  

  • 20. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
    Calza L; Borderi M; Colangeli V; Miani T; Nuti B; Bon I; Lazzarotto T; Viale P
    AIDS; 2022 Jan; 36(1):153-155. PubMed ID: 34873095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.